Parenteral and oral pharmacotherapy in prevention of osteoporotic fractures in postmenopausal osteoporosis

Katarzyna Pawlak-Buś; Piotr Leszczyński

doi:10.5114/pm.2013.36598

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2013
vol. 12

Send email

Copy url:

abstract:

Review paper

Parenteral and oral pharmacotherapy in prevention of osteoporotic fractures in postmenopausal osteoporosis

Katarzyna Pawlak-Buś

,

Piotr Leszczyński

Przegląd Menopauzalny 2013; 17 (3): 271–277

DOI: https://doi.org/10.5114/pm.2013.36598

Online publish date: 2013/07/25

View full text Get citation

PlumX metrics:

Currently available drugs for the management of postmenopausal osteoporosis can confuse clinicians in daily practice. The number of new oral and therapeutic agents with a different mechanism of action can make a clinical decision to start more complex treatment than previously. This may confirm that in order to know how, when and whom to treat in postmenopausal osteoporosis, specific recommendations based on medical scientific evidence are needed. This manuscript offers compact and easily available information about antiresorptive drugs which can be used by physicians in clinical practice.

keywords:

Parenteral and oral pharmacotherapy in prevention of osteoporotic fractures in postmenopausal osteoporosis

Katarzyna Pawlak-Buś , Piotr Leszczyński

postmenopausal osteoporosis, fracture prevention, bisphosphonates, denosumab, strontium ranelate, raloxifene, teriparatide

Katarzyna Pawlak-Buś

,

Piotr Leszczyński